The UK has a long-standing reputation as a world leader in the research and development of new medicines and for operating a high-quality life sciences industry. With the Brexit era upon us and significant changes taking place in R&D and healthcare globally, drug discovery becoming more open and collaborative,.Dr Chris Doherty of Alderley Park discusses why this is a good time to explore how we can build on the UK’s strengths.
[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/07/Driving-sci-tech-growth-in-the-UK-regions.pdf” width=”100%” height=”900px” style=”border:0;”]
